Theophylline/ephedrine

Last updated

Theophylline/ephedrine
Combination of
Theophylline Adenosine receptor antagonist
Ephedrine Norepinephrine releasing agent
Clinical data
Trade names Franol, others [1] [2]
Other namesTheophylline/ephedrine; Theophylline-(–)-ephedrine compound; Theophylline-ephedrine
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII

Theophylline ephedrine (INN Tooltip International Nonproprietary Name), or theophylline/ephedrine, sold under the brand name Franol among others, [1] is a fixed-dose combination formulation of theophylline, an adenosine receptor antagonist, and ephedrine, a norepinephrine releasing agent and indirectly acting sympathomimetic agent, which has been used as a bronchodilator in the treatment of asthma and as a nasal decongestant. [3] [4] [5] [6] [7] [8] [9] [2] It was first studied and used to treat asthma in the 1930s or 1940s and combinations of the two drugs subsequently became widely used. [9] [7] [10] A ratio of 5:1 theophylline to ephedrine is usually used in combinations of the drugs. [11] Later research found that the combination was no more effective for asthma than theophylline alone but produced more side effects however. [9] [1] [12] [7]

Combinations of theophylline, ephedrine, and phenobarbital (brand name Tedral among others) have also been widely used to treat asthma. [12] [13] [14] [15] Many such combinations have been marketed with numerous brand names. [15] Theophylline has also been marketed in combination with other ephedrine-like sympathomimetics like racephedrine and pseudoephedrine and with other barbiturates such as amobarbital and butabarbital, among other drugs. [15] A combination of theophylline, ephedrine, and hydroxyzine has been marketed under the brand name Marax among others as well. [16] [17] [18] Combinations of theophylline, ephedrine, and a barbiturate were later phased out in favor of combinations of theophylline and ephedrine alone (e.g., brand name Franol). [2] [1] Fixed-dose combinations of theophylline and ephedrine were abandoned after the 1970s as they did not allow for dose titration in asthma therapy owing to the toxicity of ephedrine. [19]

The effects of theophylline/ephedrine as a performance-enhancing drug in exercise and sports have been studied. [20] [21] Use of theophylline/ephedrine combinations has led to disqualification of elite athletes due to ephedrine being banned in competitive sports. [22]

See also

Related Research Articles

<span class="mw-page-title-main">Asthma</span> Long-term inflammatory disease of the airways of the lungs

Asthma is a long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and easily triggered bronchospasms. Symptoms include episodes of wheezing, coughing, chest tightness, and shortness of breath. These may occur a few times a day or a few times per week. Depending on the person, asthma symptoms may become worse at night or with exercise.

An allergen is an otherwise harmless substance that triggers an allergic reaction in sensitive individuals by stimulating an immune response.

<span class="mw-page-title-main">Theophylline</span> Drug used to treat respiratory diseases

Theophylline, also known as 1,3-dimethylxanthine, is a drug that inhibits phosphodiesterase and blocks adenosine receptors. It is used to treat chronic obstructive pulmonary disease (COPD) and asthma. Its pharmacology is similar to other methylxanthine drugs. Trace amounts of theophylline are naturally present in tea, coffee, chocolate, yerba maté, guarana, and kola nut.

A bronchodilator or broncholytic is a substance that dilates the bronchi and bronchioles, decreasing resistance in the respiratory airway and increasing airflow to the lungs. Bronchodilators may be originating naturally within the body, or they may be medications administered for the treatment of breathing difficulties, usually in the form of inhalers. They are most useful in obstructive lung diseases, of which asthma and chronic obstructive pulmonary disease are the most common conditions. Although this remains somewhat controversial, they might be useful in bronchiolitis and bronchiectasis. They are often prescribed but of unproven significance in restrictive lung diseases.

<span class="mw-page-title-main">Pseudoephedrine</span> Pharmaceutical drug

Pseudoephedrine, sold under the brand name Sudafed among others, is a sympathomimetic medication which is used as a decongestant to treat nasal congestion. It has also been used off-label for certain other indications, like treatment of low blood pressure. At higher doses, it may produce various additional effects, including psychostimulant, appetite suppressant, and performance-enhancing effects. In relation to this, non-medical use of pseudoephedrine has been encountered. The medication is taken by mouth.

<span class="mw-page-title-main">Ephedrine</span> Medication and stimulant

Ephedrine is a central nervous system (CNS) stimulant and sympathomimetic agent that is often used to prevent low blood pressure during anesthesia. It has also been used for asthma, narcolepsy, and obesity but is not the preferred treatment. It is of unclear benefit in nasal congestion. It can be taken by mouth or by injection into a muscle, vein, or just under the skin. Onset with intravenous use is fast, while injection into a muscle can take 20 minutes, and by mouth can take an hour for effect. When given by injection, it lasts about an hour, and when taken by mouth, it can last up to four hours.

Theophylline/ephedra/hydroxyzine is a drug that was used for the treatment of asthma. It was a combination of theophylline, ephedra, and hydroxyzine, and taken by mouth. It is no longer manufactured in the US due to approval of ephedra being withdrawn by the FDA.

<span class="mw-page-title-main">Fexofenadine</span> Antihistamine medication

Fexofenadine, sold under the brand name Allegra among others, is an antihistamine pharmaceutical drug used in the treatment of allergy symptoms, such as hay fever and urticaria.

<span class="mw-page-title-main">Omalizumab</span> Monoclonal antibody medication

Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), and immunoglobulin E-mediated food allergy.

<span class="mw-page-title-main">Phenylephrine</span> Decongestant medication

Phenylephrine, sold under the brand names Neosynephrine and Sudafed PE among numerous others, is a medication used as a decongestant for uncomplicated nasal congestion, used to dilate the pupil, used to increase blood pressure, and used to relieve hemorrhoids. It can be taken by mouth, as a nasal spray, given by injection into a vein or muscle, applied to the skin, or as a rectal suppository.

<span class="mw-page-title-main">Aspirin-exacerbated respiratory disease</span> Chronic inflammatory disease affecting the sinuses and lungs

Aspirin-exacerbated respiratory disease (AERD), also called NSAID-exacerbated respiratory disease (N-ERD) or historically aspirin-induced asthma and Samter's Triad, is a long-term disease defined by three simultaneous symptoms: asthma, chronic rhinosinusitis with nasal polyps, and intolerance of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). Compared to aspirin tolerant patients, AERD patients' asthma and nasal polyps are generally more severe. Reduction or loss of the ability to smell is extremely common, occurring in more than 90% of people with the disease. AERD most commonly begins in early- to mid-adulthood and has no known cure. While NSAID intolerance is a defining feature of AERD, avoidance of NSAIDs does not affect the onset, development or perennial nature of the disease.

<span class="mw-page-title-main">Allergen immunotherapy</span> Medical treatment for environmental allergies

Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for environmental allergies and asthma. Immunotherapy involves exposing people to larger and larger amounts of allergens in an attempt to change the immune system's response.

<span class="mw-page-title-main">Bronchoconstriction</span> Constriction of the terminal airways in the lungs

Bronchoconstriction is the constriction of the airways in the lungs due to the tightening of surrounding smooth muscle, with consequent coughing, wheezing, and shortness of breath.

Dorzolamide/timolol, sold under the brand name Cosopt among others, is a medication used to treat high pressure inside the eye including glaucoma. It is a combination of dorzolamide hydrochloride and timolol maleate. It may be used when a beta blocker, like timolol, is not sufficient alone. It is used as an eye drop.

<span class="mw-page-title-main">Lamivudine/zidovudine</span> Combination drug for HIV

Lamivudine/zidovudine, sold under the brand name Combivir among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains two antiretroviral medications, lamivudine and zidovudine. It is used together with other antiretrovirals. It is taken by mouth twice a day.

<span class="mw-page-title-main">Azelastine</span> Chemical compound

Azelastine, sold under the brand name Astelin among others, is a H1 receptor-blocking medication primarily used as a nasal spray to treat allergic rhinitis (hay fever) and as eye drops for allergic conjunctivitis. Other uses may include asthma and skin rashes for which it is taken by mouth. Onset of effects is within minutes when used in the eyes and within an hour when used in the nose. Effects last for up to 12 hours.

<span class="mw-page-title-main">Bitolterol</span> Chemical compound

Bitolterol mesylate (Tornalate) is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and COPD. In these disorders there is a narrowing of the airways that carry air to the lungs. Muscle spasm and inflammation within the bronchi worsen this narrowing. Bitolterol relaxes the smooth muscles present continuously around the bronchi and bronchioles facilitating the flow of air through them.

<span class="mw-page-title-main">Budesonide</span> Type of corticosteroid medication

Budesonide, sold under the brand name Pulmicort, among others, is a steroid medication. It is available as an inhaler, nebulization solution, pill, nasal spray, and rectal forms. The inhaled form is used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD). The nasal spray is used for allergic rhinitis and nasal polyps. Modified-release pills or capsules and rectal forms may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis, and microscopic colitis.

Tedral, or theophylline/ephedrine/phenobarbital, is a medicine formerly used to treat respiratory diseases such as asthma, chronic obstructive lung disease (COPD), chronic bronchitis, and emphysema. It is a combination drug containing three active ingredients - theophylline, ephedrine, phenobarbital. This medication relaxes the smooth muscle of the airways, making breathing easier. The common side effects of Tedral include gastrointestinal disturbances, dizziness, headache and lightheadedness. However, at high dose, it may lead to cardiac arrhythmias, hypertension, seizures or other serious cardiovascular and/or central nervous system adverse effects. Tedral is contraindicated in individuals with hypersensitivity to theophylline, ephedrine and/or phenobarbital. It should be also used in caution in patients with cardiovascular complications, such as ischemic heart disease and heart failure and/or other disease conditions. It can cause a lot of drug–drug interactions. Therefore, before prescribing patient with Tedral, drug interactions profile should be carefully checked if the patient had other concurrent medication(s). Being used as a treatment option for respiratory diseases for decades, Tedral was withdrawn from the US market in 2006 due to safety concerns.

Anti-asthmatic agents refer to drugs that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies and related hospital visits.

References

  1. 1 2 3 4 Mansfield PR (1991). "Classifying improvements to drug marketing and justifications for claims of efficacy". The International Journal of Risk & Safety in Medicine. 2 (4): 171–184. doi:10.3233/JRS-1991-2401. PMID   23511913. Dr Lathem, Sterling's Vice President for Scientific Affairs replied to MaLAM that "Franol is approved for marketing in the United Kingdom in a formulation containing theophylline and ephedrine. We have initiated a re-formulation worldwide to make all Franol formulations consistent with those of the U.K.". Weinberger and Bronsky (1974) compared theophylline and ephedrine separately and combined. They concluded that "the inclusion of ephedrine resulted in no further benefit but did appear to increase the frequency of adverse effects" [26].
  2. 1 2 3 Head S (2022). "A breath of fresh air". Prescriber. 33 (2): 41–42. doi:10.1002/psb.1973. ISSN   0959-6682. Amesec contained ephedrine and amylobarbitone with a whiff of aminophylline. Franol contained ephedrine and theophylline, and earlier versions also contained phenobarbital.
  3. Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 1179. ISBN   978-1-4757-2085-3 . Retrieved 29 August 2024.
  4. "INN Proposed List 14". World Health Organization (WHO). 31 October 1964. Retrieved 29 August 2024.
  5. National Archives (U.S.) (1978). Federal Register (in German). Office of the Federal Register, National Archives and Records Service, General Services Administration. pp. 12450–12382. Retrieved 30 August 2024.
  6. Sims JA, doPico GA, Reed CE (July 1978). "Bronchodilating effect of oral theophylline-ephedrine combination". The Journal of Allergy and Clinical Immunology. 62 (1): 15–21. doi:10.1016/0091-6749(78)90066-0. PMID   350932.
  7. 1 2 3 Weinberger M, Bronsky E, Bensch GW, Bock GN, Yecies JJ (May 1975). "Interaction of ephedrine and theophylline". Clinical Pharmacology and Therapeutics. 17 (5): 585–592. doi:10.1002/cpt1975175585. PMID   1092514. Brown1 reported uncontrolled clinical observations suggesting the apparent effectiveness of a fixed dose combination of ephedrine and theophylline in 1940, Such preparations have become very popular, though a search of the literature since that initial report unearthed only one controlled study (of very limited scope) that suggested additive effect from drug combination.15
  8. Pinnas JL, Schachtel BP, Chen TM, Roseberry HR, Thoden WR (March 1991). "Inhaled epinephrine and oral theophylline-ephedrine in the treatment of asthma". Journal of Clinical Pharmacology. 31 (3): 243–247. doi:10.1002/j.1552-4604.1991.tb04969.x. PMID   2019665.
  9. 1 2 3 Stargrove M, Treasure J, McKee D (2007). Herb, Nutrient, and Drug Interactions: Clinical Implications and Therapeutic Strategies. Elsevier Health Sciences. p. 45. ISBN   978-0-323-02964-3 . Retrieved 2024-08-31. Theophylline is generally more potent than caffeine in its effects; it was often combined with ephedrine in nasal decongestant products before more selective adrenergic blockers became available. An early study found the theophylline-ephedrine combination no more effective than theophylline alone in 23 asthmatic children, whereas the ADR rate was higher for the combination than for theophylline.40 Another study of asthmatic children, however, showed no additional adverse effects from the combination.
  10. Weinberger M, Hendeles L (October 1986). "Therapeutic effect and dosing strategies for theophylline in the treatment of chronic asthma". The Journal of Allergy and Clinical Immunology. 78 (4 Pt 2): 762–768. doi:10.1016/0091-6749(86)90058-8. PMID   3534057. Theophylline has undergone a major transition in clinical use over the past 10 to 15 years. Used primarily for its cardiovascular effects in the early part of this century, theophylline was found in the 1920s to have clinically beneficial effects on acute bronchospasm.1 In the 1930s, theophylline became popular as an oral agent, particularly in fixed-dose combination with ephedrine. Its predominant use continued in this manner into the early 1970s. Since then, definition of the pharmacodynamics and pharmacokinetics of theophylline has led to its present use as a major prophylactic agent for the prevention of chronic asthma.
  11. O'Loughlin JM (March 1979). "Drug therapy of bronchial asthma". The Medical Clinics of North America. 63 (2): 391–396. PMID   35721.
  12. 1 2 Hendeles L, Weinberger M (1980). "Avoidance of adverse effects during chronic therapy with theophylline". European Journal of Respiratory Diseases. Supplement. 109: 103–119. PMID   7002576. Until recently, combination products containing theophylline, ephedrine, and a "sedative" were the most frequently prescribed bronchodilators in the United States. Several studies, however, have documented that the combination of ephedrine and theophylline produce synergistic toxicity without significantly enhancing the therapeutic efficacy of theophylline alone (Figure 1).
  13. Khouzam H, Tan D, Gill T (2007). Handbook of Emergency Psychiatry. Elsevier Health Sciences. p. 53. ISBN   978-0-323-07661-6 . Retrieved 30 August 2024.
  14. Heinzelman RV (1972). Annual Reports in Medicinal Chemistry. ISSN. Elsevier Science. p. 92. ISBN   978-0-08-058351-8 . Retrieved 30 August 2024.
  15. 1 2 3 Project Label: Alphabetical Listing by Drug Product. Department of Justice, Drug Enforcement Administration, Office of Compliance and Regulatory Affairs, Regulatory Support Division, Information Systems Section. 1979. Retrieved 2024-08-31.
  16. Emergency Medical Care: A Manual for the Paramedic in the Field. Emergency Medical Care: A Manual for the Paramedic in the Field. U.S. Department of Transportation, National Highway Traffic Safety Administration. 1983. p. 3-PA33. Retrieved 31 August 2024.
  17. Emergency Department Trends from the Drug Abuse Warning Network: Preliminary Estimates January-June 2001 with Revised Estimates 1994-2000. DHHS publication. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. 2002. p. 210. Retrieved 31 August 2024.
  18. Mosby's Pocket Dictionary of Medicine, Nursing & Health Professions - E-Book: Mosby's Pocket Dictionary of Medicine, Nursing & Health Professions - E-Book. Elsevier Health Sciences. 2016. p. 810. ISBN   978-0-323-41427-2 . Retrieved 31 August 2024.
  19. Akazawa M, Stempel DA (2006). "Single-inhaler combination therapy for asthma: a review of cost effectiveness". PharmacoEconomics. 24 (10): 971–988. doi:10.2165/00019053-200624100-00005. PMID   17002480. The concept of using a single therapy and maximising the dose of ICS might have been driven by the desire to avoid fixed combinations. These were commonly used in the US during the 1970s with products such as Tedral®1 and Marax® that combined theophylline and ephedrine with a sedative. The earlier fixed combinations did not allow for significant dose titration, due to the toxicity of ephedrine, and thus the concept of fixed dosing combinations for asthma was relegated to an 'unacceptable' status.
  20. Kennedy M (January 2021). "Effects of theophylline and theobromine on exercise performance and implications for competition sport: A systematic review". Drug Testing and Analysis. 13 (1): 36–43. doi:10.1002/dta.2970. PMID   33188564.
  21. Sidney KH, Lefcoe NM (1978). "Effects of anti-asthmatic medication (ephedrine plus theophylline) upon the physical performance and work capacity of healthy track athletes". Can J Appl Sport Sci. 3: 93–97.
  22. Helenius I, Haahtela T (September 2000). "Allergy and asthma in elite summer sport athletes". The Journal of Allergy and Clinical Immunology. 106 (3): 444–452. doi:10.1067/mai.2000.107749. PMID   10984362. Team physicians became interested in asthma in elite athletes after the 1972 Olympic Games in Munich. The winner of the men's 400 m freestyle swimming race was disqualified because a significant amount of a banned drug, ephedrine, was found in his postrace urinalysis sample. The swimmer had used a combination preparation of theophylline and ephedrine for the treatment of his asthma. Since then both US and Australian Olympic Committees have put special emphasis on the accurate diagnosis and treatment of asthma in their Olympic teams.1,2